Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR)

NCT02374957 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT02374957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02374957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR)
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 4
Overall status
Terminated
Start date
February 28, 2015
Completion date
June 30, 2017
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

claudication (finding), peripheral arterial disease